SurgiLight
This article was originally published in The Gray Sheet
Executive Summary
Laser developer's $30 mil. standby equity-based financing agreement with an institutional investor will help fund clinical trials of the IR-3000 laser system for presbyopia correction and rollout of the FDA-cleared EX308 laser for treatment of psoriasis. Resale of shares issued by the Orlando, Florida company under the agreement is expected to commence "in the early part of 2001," J.T. Lin, PhD, company president and CEO, remarked